Positive U.S. Same Market Treatment Growth
The underlying U.S. same market treatment growth turned positive in Q3 with 0.2% growth, adjusted for the exit of acute contracts, including a 5 basis point negative impact from the hurricanes.
Strong International Business Performance
International business saw same market treatment growth accelerate to 3%, indicating strong underlying trends and effective portfolio optimization.
Increased Operating Income and Margins
Both operating segments realized increased operating income and margins, with Care Delivery reaching a margin of 11.2%, which is within the 2025 target band.
Successful FME25 Program Acceleration
The FME25 program contributed EUR 64 million in additional savings, with expectations to achieve around EUR 200 million by the end of 2024, surpassing the target.
Reduction in Net Financial Debt
The company reduced its net financial debt and improved its net leverage ratio to 2.8x, below the target corridor of 3x to 3.5x.